Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « modifying »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
modify < modifying < mods  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 38.
[0-20] [0 - 20][0 - 38][20-37][20-40]
Ident.Authors (with country if any)Title
000058 (2020) Masaki Shimizu [Japon] ; Mao Mizuta [Japon] ; Nami Okamoto [Japon] ; Takahiro Yasumi [Japon] ; Naomi Iwata [Japon] ; Hiroaki Umebayashi [Japon] ; Yuka Okura [Japon] ; Noriko Kinjo [Japon] ; Tomohiro Kubota [Japon] ; Yasuo Nakagishi [Japon] ; Kenichi Nishimura [Japon] ; Mariko Mohri [Japon] ; Masato Yashiro [Japon] ; Junko Yasumura [Japon] ; Hiroyuki Wakiguchi [Japon] ; Masaaki Mori [Japon]Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
000082 (2020) Eun-Jung Park [Corée du Sud] ; Hyungjin Kim [Corée du Sud] ; Seung Min Jung [Corée du Sud] ; Yoon-Kyoung Sung [Corée du Sud] ; Han Joo Baek [Corée du Sud] ; Jisoo Lee [Corée du Sud]The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
000118 (2020) Gregory S. Calip [États-Unis] ; Pritesh R. Patel [États-Unis] ; Karen Sweiss [États-Unis] ; Zhaoju Wu [États-Unis] ; Jifang Zhou [États-Unis] ; Alemseged A. Asfaw [États-Unis] ; Sruthi Adimadhyam [États-Unis] ; Todd A. Lee [États-Unis] ; Brian C-H Chiu [États-Unis]Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma.
000139 (2020) Chayma Ladhari [France] ; Pierre Le Blay [France] ; Thierry Vincent [France] ; Ahmed Larbi [France] ; Emma Rubenstein [France] ; Rosanna Ferreira Lopez [France] ; Christian Jorgensen [France] ; Yves-Marie Pers [France]Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
000143 (2020) Eduardo Mysler [Argentine] ; Mario H. Cardiel [Mexique] ; Ricardo M. Xavier [Brésil] ; Alejandra L Pez ; Allan Ramos-Esquivel [Costa Rica]Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.
000151 (2020) Joanna Wai Yee Leong [Singapour] ; Peter P. Cheung [Singapour] ; Sajeewani Dissanayake [Singapour] ; Warren Weng Seng Fong [Singapour] ; Keng Hong Leong [Singapour] ; Ying Ying Leung [Singapour] ; Anita Yee Nah Lim [Singapour] ; Nai Lee Lui [Singapour] ; Mona Manghani [Singapour] ; Amelia Santosa [Singapour] ; Melonie Kannamma Sriranganathan [Singapour] ; Ernest Suresh [Singapour] ; Teck Choon Tan [Singapour] ; Gim Gee Teng [Singapour] ; Manjari Lahiri [Singapour]Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
000162 (2020) Alexandre Sepriano [Oman] ; Andreas Kerschbaumer [Autriche] ; Josef S. Smolen [Autriche] ; Désirée Van Der Heijde [Pays-Bas] ; Maxime Dougados [France] ; Ronald Van Vollenhoven [Pays-Bas] ; Iain B. Mcinnes [Royaume-Uni] ; Johannes W. Bijlsma [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maarten De Wit [Suisse] ; Louise Falzon [États-Unis] ; Robert Landewé [Pays-Bas]Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
000164 (2020) Giulia Cassone ; Andreina Manfredi ; Fabiola Atzeni ; Vincenzo Venerito ; Caterina Vacchi ; Valentina Picerno ; Federica Furini ; Gian Luca Erre ; Paola Tomietto ; Anna Laura Fedele [Italie] ; Giovanni Della Casa [Italie] ; Valeria Nucera ; Chiara Giannitti [Italie] ; Carlo Salvarani ; Marco SebastianiSafety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study
000166 (2020) Elyes Bouajina [Tunisie] ; Leith Zakraoui [Tunisie] ; Montassar Kchir [Tunisie] ; Samir Kochbati [Tunisie] ; Sofiene Baklouti [Tunisie]Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice.
000169 (2020) Maria Antonietta Barbieri [Italie] ; Giuseppe Cicala [Italie] ; Paola Maria Cutroneo [Italie] ; Elisabetta Gerratana [Italie] ; Caterina Palleria [Italie] ; Caterina De Sarro [Italie] ; Ada Vero [Italie] ; Luigi Iannone [Italie] ; Antonia Manti [Italie] ; Emilio Russo [Italie] ; Giovambattista De Sarro [Italie] ; Fabiola Atzeni [Italie] ; Edoardo Spina [Italie]Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study.
000187 (2020) Durga Prasanna Misra [Inde] ; Vikas Agarwal [Inde] ; Armen Yuri Gasparyan ; Olena Zimba [Ukraine]Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets
000204 (2020) Jennie H. Best [États-Unis] ; Steven C. Vlad [États-Unis] ; Lenore Tominna [États-Unis] ; Ibrahim Abbass [États-Unis]Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic.
000218 (2020) Piero Ruscitti [Italie] ; Paola Cipriani [Italie] ; Vasiliki Liakouli [Italie] ; Daniela Iacono [Italie] ; Ilenia Pantano [Italie] ; Francesco Caso [Italie] ; Federico Perosa [Italie] ; Fabiola Atzeni [Italie] ; Francesco Paolo Cantatore [Italie] ; Raffaele Scarpa [Italie] ; Francesco Ciccia [Italie] ; Roberto Giacomelli [Italie]Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.
000293 (2020) Hermine I. Brunner [États-Unis] ; Nikolay Tzaribachev [Allemagne] ; Gabriel Vega Cornejo ; Rik Joos [Belgique] ; Elisabeth Gervais [France] ; Rolando Cimaz [Italie] ; Inmaculada Calvo Penadés [Espagne] ; Rubén Cuttica [Argentine] ; Thomas Lutz [Allemagne] ; Pierre Quartier [France] ; Yash Gandhi [États-Unis] ; Marleen Nys [Belgique] ; Robert Wong [États-Unis] ; Alberto Martini [Italie] ; Daniel J. Lovell [États-Unis] ; Nicolino Ruperto [Italie]Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept
000306 (2020) Grant Broussard [États-Unis] ; Blossom Damania [États-Unis]KSHV: Immune Modulation and Immunotherapy
000311 (2020) Durga Prasanna Misra [Inde] ; Sakir Ahmed [Inde] ; Vikas Agarwal [Inde]Is biological therapy in systemic sclerosis the answer?
000324 (2020) Sae Ochi [Japon] ; Kazuyoshi Saito [Japon] ; Fumitaka Mizoguchi [Japon] ; Shigeaki Kato [Japon] ; Yoshiya Tanaka [Japon]Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
000348 (2020) Sisi Xie ; Shu Li ; Jing Tian ; Fen LiIguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
000367 (2020) Charlotte Hua [France] ; Frank Buttgereit [Allemagne] ; Bernard Combe [France]Glucocorticoids in rheumatoid arthritis: current status and future studies
000380 (2020) Nils Schubert [Allemagne] ; Tillmann Schill [Allemagne] ; Marlene Plü [Allemagne] ; Peter Korsten [Allemagne]Flare or foe? - Mycobacterium marinum infection mimicking rheumatoid arthritis tenosynovitis: case report and literature review
000385 (2020) Gaëlle Vial [France] ; Anaïs De Pouilly [France] ; Laetitia Scouppe [France] ; Bruno Pereira [France] ; Claire Daien [France] ; Cédric Lukas [France] ; Adeline Ruyssen-Witrand [France] ; Pascale Vergne-Salle [France] ; Christophe Richez [France] ; Anne Tournadre [France]Factors influencing the choice of biologic therapy following Rituximab in patients with rheumatoid arthritis: A retrospective study using propensity score.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "modifying" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "modifying" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    modifying
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021